DGAP-News: Woori BMO Group Comments on Bayer Spending Up To $4 Billion For Gene-Therapy Firm AskBio
"Bayer will pay $2 billion now and up to another $2 billion in cash instalments based on the units future success milestones.
- "Bayer will pay $2 billion now and up to another $2 billion in cash instalments based on the units future success milestones.
- "The overall market value for cell and gene therapy stood $4.8 billion in 2019 and is likely to grow tenfold to $44.5 billion by 2024," Harper added.
- The $63 billion Monsanto acquisition was supposed to bring the company another significant, fast-growing revenue stream in addition to pharmaceuticals.
- Bayer's drug portfolio has also been troubling investors, according to researchers at Woori BMO Group .